VB-119 is under clinical development by Acelyrin and currently in Phase II for Focal Segmental Glomerulosclerosis (FSGS). According to GlobalData, Phase II drugs for Focal Segmental Glomerulosclerosis (FSGS) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the VB-119 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
VB-119 overview
VB-119 is under development for the treatment of primary membranous nephropathy and primary focal segmental glomerulosclerosis. They act by targeting CD19. It is administered through intravenous route. The therapeutic candidate is a humanized, immunoglobin (Ig) G1 monoclonal antibody (mAb).
Acelyrin overview
Acelyrin is a biopharma company that identifies, acquires, and accelerates the development and commercialization of transformative medicines. It focuses on creating value for patients and shareholders. The company’s products include izokibep, Lonigutamab (anti-IGF-1R), XLRN-517 (anti-C-KIT). Acelyrin pipeline treats hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, uveitis, thyroid eye disease, and chronic urticaria.
For a complete picture of VB-119’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
